NEW YORK--(BUSINESS WIRE)--IRX Therapeutics today announced that John W. Hadden II, has been named President and Chief Executive Officer. He had previously been Chief Operating Officer. Harvey Brandwein, Ph.D., the former President and Chief Executive Office was named Chief Technology Officer, Senior Vice President of Research. Dr. Brandwein will continue to lead the Company’s efforts in research and manufacturing operations.
